Sensitivity and understanding at the most difficult of times

This is a preview of subscriber content

Subscribe now to continue reading.

In an interview with BioPharmaDispatch yesterday, Medicines Australia chief executive Liz de Somer made the following point, "It is a time for sensitivity and our industry needs to communicate with each other and externally mindful of the extent of this crisis and how it is very seriously impacting millions of people." …

Subscribe now to continue reading.

Sensitivity and understanding at the most difficult of times

This is a preview of subscriber content

Latest Video

Most Read

One CSL innovation that allows for a direct and timely comparison

New survey reveals role of credit cards and borrowing in healthcare access

NZ Government expands access to melatonin and psilocybin

Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant

Gilead confirms Australian submission for major HIV innovation following US approval

New Stories

WA Budget includes significant investments in health and medical research

Gilead confirms Australian submission for major HIV innovation following US approval

Advocate and founder of Rare Cancers Australia steps down as chair

Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant

Amplia announces second confirmed complete response in ACCENT trial

NZ Government expands access to melatonin and psilocybin

Imugene announces US patent allowance for onCARlytics

Sign In

Sensitivity and understanding at the most difficult of times

This is a preview of subscriber content

Latest Video

Most Read

One CSL innovation that allows for a direct and timely comparison

New survey reveals role of credit cards and borrowing in healthcare access

NZ Government expands access to melatonin and psilocybin

Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant

Gilead confirms Australian submission for major HIV innovation following US approval

Follow Us

New Stories

WA Budget includes significant investments in health and medical research

Gilead confirms Australian submission for major HIV innovation following US approval

Advocate and founder of Rare Cancers Australia steps down as chair

Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant

Amplia announces second confirmed complete response in ACCENT trial

NZ Government expands access to melatonin and psilocybin

Imugene announces US patent allowance for onCARlytics